Clinical data | |
---|---|
Trade names | Civanex |
Other names | Civamide; (Z)-Capsaicin; cis-Capsaicin |
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.164.527 |
Chemical and physical data | |
Formula | C18H27NO3 |
Molar mass | 305.418 g·mol−1 |
3D model (JSmol) | |
| |
|
Zucapsaicin (Civanex) is a medication used to treat osteoarthritis of the knee and other neuropathic pain. Zucapsaicin is a member of phenols and a member of methoxybenzenes.[2] It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1 that reduces pain, and improves articular functions.[3][unreliable medical source?][4] It is the cis-isomer of capsaicin. Civamide, manufactured by Winston Pharmaceuticals, is produced in formulations for oral, nasal, and topical use (patch and cream).[5][6]
Zucapsaicin has been tested for treatment of a variety of conditions associated with ongoing nerve pain. This includes herpes simplex infections; cluster headaches and migraine; and knee osteoarthritis.[7][dead link] It was approved by the Health Canada in 2010 as topical cream sold under the brand name Zuacta.[3] It has a melting point of 71.5–74.5 °C.[3]